Glucose variability; does it matter?

Overall lowering of glucose is of pivotal importance in the treatment of diabetes, with proven beneficial effects on microvascular and macrovascular outcomes. Still, patients with similar glycosylated hemoglobin levels and mean glucose values can have markedly different daily glucose excursions. The role of this glucose variability in pathophysiological pathways is the subject of debate. It is strongly related to oxidative stress in in vitro, animal, and human studies in an experimental setting. However, in real-life human studies including type 1 and type 2 diabetes patients, there is neither a reproducible relation with oxidative stress nor a correlation between short-term glucose variability and retinopathy, nephropathy, or neuropathy. On the other hand, there is some evidence that long-term glycemic variability might be related to microvascular complications in type 1 and type 2 diabetes. Regarding mortality, a convincing relationship with short-term glucose variability has only been demonstrated in nondiabetic, critically ill patients. Also, glucose variability may have a role in the prediction of severe hypoglycemia. In this review, we first provide an overview of the various methods to measure glucose variability. Second, we review current literature regarding glucose variability and its relation to oxidative stress, long-term diabetic complications, and hypoglycemia. Finally, we make recommendations on whether and how to target glucose variability, concluding that at present we lack both the compelling evidence and the means to target glucose variability separately from all efforts to lower mean glucose while avoiding hypoglycemia.

[1]  Wójcicki Jm,et al.  J"-index. A new proposition of the assessment of current glucose control in diabetic patients. , 1995 .

[2]  Michael Brownlee,et al.  Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. , 2006, JAMA.

[3]  Israel Hartman.  Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence , 2008, Clinical Medicine & Research.

[4]  L. Kennedy.  A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes , 2007 .

[5]  C. McDonnell,et al.  A novel approach to continuous glucose analysis utilizing glycemic variation. , 2005, Diabetes technology & therapeutics.

[6]  Daniel J Cox,et al.  A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. , 2006, Diabetes technology & therapeutics.

[7]  H. Chase,et al.  Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes , 2009, Diabetes Care.

[8]  James Stephen Krinsley,et al.  Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. , 2004, Mayo Clinic proceedings.

[9]  S. Yusuf,et al.  Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. , 2002, Diabetes care.

[10]  Anthony N Thomas,et al.  Evaluation of short-term consequences of hypoglycemia in an intensive care unit. , 2007, Critical care medicine.

[11]  B. Zinman,et al.  Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited , 2008, Diabetes.

[12]  H. van Lenthe,et al.  A randomized clinical trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress , 2009, Diabetes, obesity & metabolism.

[13]  Stephane Heritier,et al.  Intensive versus conventional glucose control in critically ill patients. , 2009, The New England journal of medicine.

[14]  J. Krinsley,et al.  Glycemic variability: A strong independent predictor of mortality in critically ill patients* , 2008, Critical care medicine.

[15]  H. Rasmussen,et al.  Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. , 1995, The American journal of physiology.

[16]  E. Kilpatrick.  HbA 1 c variability and the risk of microvascular complications in type 1 diabetes : data from the DCCT , 2008 .

[17]  J. Kichler,et al.  Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus. , 2007, Diabetes technology & therapeutics.

[18]  B. Anderson,et al.  Insulin pump therapy in preschool children with type 1 diabetes mellitus improves glycemic control and decreases glucose excursions and the risk of hypoglycemia. , 2005, Diabetes technology & therapeutics.

[19]  W. F. Taylor,et al.  Day-to-day variation of continuously monitored glycaemia: A further measure of diabetic instability , 1972, Diabetologia.

[20]  L. M. Lou-Arnal,et al.  Fasting plasma glucose variability as a risk factor of retinopathy in Type 2 diabetic patients. , 2003, Journal of diabetes and its complications.

[21]  A. Rigby,et al.  Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT , 2009, Diabetologia.

[22]  Hypoglycemia in the Diabetes Control and Complications Trial , 1997, Diabetes.

[23]  A. Rigby,et al.  A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes , 2008, Diabetes Care.

[24]  J. Pickup,et al.  Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability , 2006, Diabetes/metabolism research and reviews.

[25]  P. Wilson,et al.  Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial , 2009, Diabetes Care.

[26]  H. Orskov,et al.  Kidney tissue insulin-like growth factor I and initial renal growth in diabetic rats: relation to severity of diabetes. , 1990, Acta endocrinologica.

[27]  William L Clarke,et al.  Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. , 2005, Diabetes technology & therapeutics.

[28]  Antonio Ceriello,et al.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. , 2003, Diabetes.

[29]  Wójcicki Jm.  Mathematical Descriptions of the Glucose Control in Diabetes Therapy. Analysis of the Schlichtkrull “M”-Value , 1995 .

[30]  B P Kovatchev,et al.  Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. , 2000, The Journal of clinical endocrinology and metabolism.

[31]  D G Schlundt,et al.  Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. , 1994, The Journal of clinical endocrinology and metabolism.

[32]  M. Steffes,et al.  Structural-functional relationships in diabetic nephropathy. , 1984, The Journal of clinical investigation.

[33]  J. Rosenstock,et al.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. , 2003, Diabetes care.

[34]  S. Tarui,et al.  Studies on the Etiology of “Brittle Diabetes”: Relationship Between Diabetic Instability and Insulinogenic Reserve , 1977, Diabetes.

[35]  Richard M Hoffman,et al.  A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus: The Diabetes Outcomes in Veterans Study (DOVES). , 2004, Archives of internal medicine.

[36]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[37]  A. Giobbie-Hurder,et al.  Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. , 1996, JAMA.

[38]  L. Vignati,et al.  Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Archives of internal medicine.

[39]  E. Moberg,et al.  Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus. , 1993, Scandinavian journal of clinical and laboratory investigation.

[40]  Y. Yamasaki,et al.  1,5-Anhydro-D-glucitol Evaluates Daily Glycemic Excursions in Well-Controlled NIDDM , 1995, Diabetes Care.

[41]  J M Wójcicki,et al.  Mathematical Descriptions of the Glucose Control in Diabetes Therapy. Analysis of the Schlichtkrull “M”-Value , 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[42]  Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Archives of internal medicine.

[43]  G. Striker,et al.  Inhibition of diabetic nephropathy by a GH antagonist: a molecular analysis. , 1996, Kidney international.

[44]  M. Nobre,et al.  The PICO strategy for the research question construction and evidence search. , 2007, Revista latino-americana de enfermagem.

[45]  J. Wojcicki,et al.  “J”-Index. A New Proposition of the Assessment of Current Glucose Control in Diabetic Patients , 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[46]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[47]  A. Ceriello,et al.  Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction , 2006, Diabetes/metabolism research and reviews.

[48]  D. Owens,et al.  Comparison of Subcutaneous Soluble Human Insulin and Insulin Analogues (AspB9, GluB27; AspB10; AspB28) on Meal-Related Plasma Glucose Excursions in Type I Diabetic Subjects , 1991, Diabetes Care.

[49]  R. Bilous,et al.  Cell and Matrix Components of the Glomerular Mesangium in Type I Diabetes , 1992, Diabetes.

[50]  The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. , 1996, Diabetes.

[51]  Rinaldo Bellomo,et al.  Variability of Blood Glucose Concentration and Short-term Mortality in Critically Ill Patients , 2006, Anesthesiology.

[52]  Rolf Rossaint,et al.  Intensive insulin therapy and pentastarch resuscitation in severe sepsis. , 2008, The New England journal of medicine.

[53]  A. Shapiro,et al.  Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. , 2004, Diabetes.

[54]  Heather Van Duker,et al.  Alterations in glucose homeostasis in the pediatric intensive care unit: Hyperglycemia and glucose variability are associated with increased mortality and morbidity* , 2008, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[55]  Boris Kovatchev,et al.  Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. , 2009, Diabetes technology & therapeutics.

[56]  A. Rigby,et al.  Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. , 2007, Clinical chemistry.

[57]  G. Van den Berghe,et al.  Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.

[58]  A. Csordás,et al.  Rapid ‘glycaemic swings’ induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus , 2009, Diabetologia.

[59]  M. Brownlee.  Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[60]  D. Bruttomesso,et al.  In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[61]  C. Weyer,et al.  Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. , 2005, Diabetes care.

[62]  Hanqing Cao,et al.  Blood Glucose Variability is Associated with Mortality in the Surgical Intensive Care Unit , 2008, The American surgeon.

[63]  K. Griendling,et al.  Serial Review : The Role of Oxidative Stress in Diabetes mellitus Serial Review , 2006 .

[64]  W. Qi,et al.  Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells , 1999, Diabetologia.

[65]  W. F. Taylor,et al.  Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability , 1970, Diabetes.

[66]  J. Schlichtkrull,et al.  [M-VALUE, AN INDEX FOR BLOOD SUGAR CONTROL IN DIABETICS]. , 1964, Ugeskrift for laeger.

[67]  P. Oskarsson,et al.  Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? , 2008, Diabetes & metabolism.

[68]  Norman Fleischer,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .

[69]  D. Cox,et al.  Symmetrization of the Blood Glucose Measurement Scale and Its Applications , 1997, Diabetes Care.

[70]  E. Kilpatrick,et al.  Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes , 2007, Diabetologia.

[71]  I. Deary,et al.  A Structural Equation Model for Predictors of Severe Hypoglycaemia in Patients with Insulin‐dependent Diabetes Mellitus , 1997 .

[72]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[73]  Michael Brownlee,et al.  The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes , 2007, Diabetes Care.

[74]  E. de Jonge,et al.  Evaluation of short-term consequences of hypoglycemia in an intensive care unit* , 2006, Critical care medicine.

[75]  G. Jenkins,et al.  Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[76]  R. Testa,et al.  Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients , 2008, Diabetes.

[77]  J. H. de Vries,et al.  Growth hormone release after the sequential use of growth hormone releasing factor and exercise. , 1991, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[78]  J. McGill,et al.  Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. , 2003, Diabetes technology & therapeutics.

[79]  Bruce Buckingham,et al.  Association of Hypoglycemia, Hyperglycemia, and Glucose Variability With Morbidity and Death in the Pediatric Intensive Care Unit , 2006, Pediatrics.

[80]  J. DeVries,et al.  Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes , 2007, Diabetologia.